Vfend Tablets 200mg (Voriconazole)

Adult dose

Vfend tablets should be taken at least 1 hour before or 1 hour after a meal. Adults (18 years and older) and adolescents (adolescents aged 12 to under 15 years weighing 50 kg or more, and adolescents aged 15 to under 18 years of any weight) Invasive Aspergillus infections and severe fungal infections caused by Scedosporium apiospermum (the asexual form of Pseudallescheria boydii) and Fusarium species (including Fusarium solani): Administer 200 mg at 12-hour intervals Candidemia and other deep-tissue Candida infections in patients without neutropenia: Administer 200 mg at 12-hour intervals Esophageal candidiasis: Administer 200 mg at 12-hour intervals Prevention of invasive fungal infections in hematopoietic stem cell transplant patients with acute leukemia (acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome), lymphoma after treatment failure, or chronic myeloid leukemia: Administer 200 mg at 12-hour intervals Treatment should continue for the longer of the following periods: at least 14 days after resolution of symptoms or at least 14 days after the last positive culture result. Esophageal candidiasis: Treatment should continue for at least 14 days and for at least 7 days after symptoms resolve. If the patient's response to treatment is inadequate, the maintenance dose (oral) may be increased from 200 mg per dose at 12-hour intervals to 300 mg per dose at 12-hour intervals in patients weighing 40 kg or more. If the patient cannot tolerate this increased dose, gradually decrease it in 50 mg increments until the dose is 200 mg per dose at 12-hour intervals for patients weighing 40 kg or more. Phenytoin may be coadministered if the maintenance dose is increased from 200 mg per dose at 12-hour intervals to 400 mg per dose at 12-hour intervals. The duration of treatment is determined by the patient's medical history, recovery from immunosuppressive therapy, and clinical response. Older adults: No dosage adjustment is necessary. In patients with mild to moderate cirrhosis (Child-Pugh A, B), the loading dose should be the standard dose and the maintenance dose should be half the standard dose. No dosage adjustment is necessary for oral administration in patients with mild to severe renal impairment.

Child dose

Patients weighing 40 kg or more: Administer 200 mg at 12-hour intervals. Patients weighing less than 40 kg: Administer 100 mg at 12-hour intervals. For patients weighing less than 40 kg, the dose may be increased from 100 mg per dose at 12-hour intervals to 150 mg per dose at 12-hour intervals. For patients weighing less than 40 kg, reduce the dose to 100 mg per dose at 12-hour intervals. For patients weighing less than 40 kg, the dose may be increased from 100 mg per dose at 12-hour intervals to 200 mg per dose at 12-hour intervals.

This drug contains voriconazole, an antifungal agent, and should not be administered to certain patients. Individuals allergic to voriconazole or its excipients should not use this drug. Additionally, since it contains lactose, patients with lactose intolerance or related genetic disorders should avoid it. This drug is metabolized in the liver and is affected by certain enzymes, particularly CYP3A4; taking it with other drugs that strongly act on this enzyme can be risky. Especially, it should not be used in combination with certain cardiac medications or immunosuppressants. Also, taking drugs that induce CYP3A4 together with this drug may reduce its efficacy, so such combinations should be avoided. Patients with hypersensitivity, heart disease, electrolyte abnormalities, or at risk of arrhythmias should use it with caution. Furthermore, monitoring is needed when this drug is combined with certain anticonvulsants or antivirals due to fluctuations in drug concentration. Regular liver function tests should be performed to check for hepatotoxicity, and if significant liver function abnormalities are noted, drug administration may be discontinued. Kidney function should also be periodically checked for abnormalities. If skin rashes or severe skin reactions occur, administration should be immediately stopped and a doctor should be consulted. This drug may cause visual disturbances, so attention is required if symptoms appear, and driving or operating hazardous machinery should be avoided. Long-term use may increase the risk of skin cancer, so regular skin checks should be conducted. During pregnancy, it should not be used except in special cases due to risks to the fetus, and women of childbearing potential must use effective contraception during treatment. It is recommended to stop breastfeeding if nursing. In cases of overdose, there are no specific antidotes; treatment should be symptomatic and supportive, and hemodialysis can help remove the drug. This drug should be kept out of the reach of children and stored in the original container to prevent misuse or degradation in quality.

Visual impairment, abnormal liver function tests, fever, rash, vomiting, nausea, diarrhea, headache, peripheral edema, abdominal pain, sinusitis, pseudomembranous colitis, agranulocytosis, pancytopenia, thrombocytopenia, leukopenia, anemia, bone marrow failure, lymphadenopathy, eosinophilia, disseminated intravascular coagulation, hypersensitivity, anaphylaxis-like reaction, adrenal insufficiency, hypothyroidism, hyperthyroidism, hypoglycemia, hypokalemia, hyponatremia, depression, hallucinations, anxiety, insomnia, restlessness, confusion, convulsions, syncope, tremors, excessive muscle tension, sensory disturbances, drowsiness, dizziness, cerebral edema, encephalopathy, extrapyramidal disorders, peripheral neuropathy, ataxia, perceptual disturbances, taste disturbances, hepatic encephalopathy, Guillain-Barré syndrome, eye tremors, retinal hemorrhage, optic nerve disorders, papilledema, ocular movement seizures, diplopia, scleritis, blepharitis, optic atrophy, corneal opacity, hearing loss, vertigo, tinnitus, ventricular arrhythmias, tachycardia, bradycardia, ventricular fibrillation, ventricular ectopic beats, ventricular tachycardia, QT prolongation on electrocardiogram, supraventricular tachycardia, torsades de pointes, complete heart block, bundle branch block, nodal rhythm, hypotension, phlebitis, thrombophlebitis, lymphangitis, acute respiratory distress syndrome, pulmonary edema, cheilitis, dyspepsia, constipation, gingivitis, peritonitis, pancreatitis, tongue edema, duodenitis, gastroenteritis, glossitis, jaundice, cholestatic jaundice, hepatitis, liver failure, hepatomegaly, cholecystitis, cholelithiasis, exfoliative dermatitis, hair loss, maculopapular rash, pruritus, erythema, Stevens-Johnson syndrome, photosensitivity reaction, purpura, urticaria, macular rash, papular rash, allergic dermatitis, eczema, toxic epidermal necrolysis, angioedema, pseudo porphyria, erythema multiforme, psoriasis, drug eruption, lupus erythematosus, drug reaction with eosinophilia and systemic symptoms, freckles, pigmented lesions, back pain, arthritis, acute kidney injury, hematuria, renal tubular necrosis, proteinuria, nephritis, chest pain, facial edema, asthenia, chills, injection site reactions, influenzalike illness, increased serum creatinine, elevated blood urea nitrogen, increased serum cholesterol, taste abnormalities, blurred vision, photophobia, green vision, color vision deficiency, blue vision, ocular diseases, halos, night blindness, tremor vision, photopsia, flash visual scotoma, decreased visual acuity, increased brightness of vision, visual field defects, vitreous floaters, yellow vision, exacerbation of hepatitis, septic shock, sepsis, exacerbation of pneumonia, pulmonary hemorrhage, pneumothorax, decreased oxygen saturation, pleural effusion, gastroesophageal reflux, gastric ulcer, gastric perforation, exacerbation of colitis, anorexia, thrombocytopenia, febrile neutropenia, neutropenia, malignant oropharyngeal neoplasm, exacerbation of rectal cancer, graft-versus-host disease, thrombotic thrombocytopenic purpura, cardiac arrest, atrial fibrillation, cerebral hemorrhage, pericardial effusion, hyperkalemia, azotemia, dry eyes, tension/tonic seizures, ear discharge.

This drug should be stored in a tightly closed container to prevent air or moisture ingress, and it is best kept in a cool place at or below 25 degrees Celsius. Storing it this way will help maintain its efficacy over time.

Appearance

White to off-white oval film-coated tablets

Package unit

14 tablets (7 tablets/blister x 2)